An observational study in Metabolic Dysfunction Associated Steatohepatitis (MASH), sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.
Among the 28 studies in Fatty Liver with a site in Spain, this one is one of 3 that started in 2025, is one of 5 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 24th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 20–80
Consorcio Centro de Investigación Biomédica en Red (CIBER) · Sites in Spain
Ages 40+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 31 more countries
Ages 18+
Boehringer Ingelheim · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
GlaxoSmithKline · Sites in Spain, United States, Argentina and 16 more countries
Ages 18–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 150 across 207 observational studies indexed under Fatty Liver.
Median enrollment 165 across the 23 interventional studies, 450 across the 5 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 343 studies on the registry; 65 are open to participants now.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau has 3 studies filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
3 of the studies in Fatty Liver with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07652892Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauImpact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective. | 2027-02-25 |
| NCT07467512Consorcio Centro de Investigación Biomédica en Red (CIBER)Exercise for an Aging Liver (EXALIVER) | 2027-06 |
| NCT06613698GlaxoSmithKlineA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | 2027-11-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Fatty Liver with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this qualitative study is to explore and identify the expectations, perceptions, attitudes, needs, and knowledge related to the management of metabolic dysfunction-associated steatohepatitis (MASH) in patients diagnosed with this condition, before and after their participation in the MASH-Cardiovascular Programme at Hospital de la Santa Creu i Sant Pau, Barcelona.
The main research question is:
What expectations, attitudes, needs, and perceptions do patients with MASH participating in the MASH-Cardiovascular Programme exhibit before and after the intervention?
Participants will undergo two semi-structured interviews: one prior to, and one following, their involvement in the MASH-Cardiovascular Programme at Hospital de Sant Pau i la Santa Creu, Barcelona.
The study population will consist of individuals diagnosed with MASH who are referred to the multidisciplinary MASH-Cardiovascular Programme at Hospital de la Santa Creu i Sant Pau in Barcelona.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Perceptions
Perceptions explored through semi-structured interviews
Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)
Attitudes and expectatives
Attitudes and expectatives explored through semi-structured interviews
Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)
MASH-related knowledge
MASH-related knowledge explored through semi-structured interviews
Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)
Unmet needs
Unmet needs explored through semi-structured interviews
Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 88 non-industry observational studies under Fatty Liver, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 68. This study's planned 30 months is below that.
Counting every sponsor, half of 97 studies reached it within 33 months; a quarter within 20 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau →